January 25, 2017 -- Suzhou Connect Biopharma raised a total of $25 million in two tranches: $20 million in a Series A round led by Qiming, and slightly earlier, $5 million in a pre-A financing. Founded in 2012, Connect is developing several G-protein coupled receptor antagonists to treat autoimmune diseases and cancer. Its lead molecule, CBP-307, has completed a Phase I trial in Australia as a treatment for inflammatory bowel disease (IBD). Connect discovers its own candidates and also in-licenses other projects. It conducts early development in-house and uses CROs for later work.
